ALNY vs. BBIO: Alnylam Pharmaceuticals vs. BridgeBio Pharma Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and BridgeBio Pharma (BBIO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ALNY | BBIO |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | BridgeBio Pharma Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 14.47 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | June 27, 2019 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Total Return (1Y) | -64.57% | 22.70% |
| Total Return (3Y, Annualized) | -1.58% | 40.97% |
| Total Return (5Y, Annualized) | -3.13% | 8.25% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 44.39% |
| Beta (5Y) | 0.45 | 0.93 |
| Max Drawdown (5Y) | -68.25% | -89.79% |
| Avg. Volume (3M) | 1.90M | 2.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.41 |
| Sortino Ratio (1Y) | -1.45 | 0.63 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Alnylam Pharmaceuticals (ALNY) earns 138.07% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
Net Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 52.85%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
Operating Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 23.72%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| ROE (TTM) | 138.07% | -- |
| ROA (TTM) | 9.51% | -13.97% |
| Net Margin (TTM) | 52.85% | -59.84% |
| Operating Margin (TTM) | 23.72% | -3.30% |
| Gross Margin (TTM) | 77.28% | 94.34% |
Growth
Revenue Growth
Both Alnylam Pharmaceuticals (ALNY) at 65.19% and BridgeBio Pharma (BBIO) at 126.26% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.
EPS Growth
Neither Alnylam Pharmaceuticals (ALNY) nor BridgeBio Pharma (BBIO) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 126.26% |
| Revenue Growth (3Y CAGR) | 52.98% | 86.30% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Alnylam Pharmaceuticals (ALNY) carries debt-to-equity ratio of 0.83 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
Financial Strength Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 2.09 |
| Debt / Equity (MRQ) | 0.83 | -- |
| Net Debt / EBITDA | -0.57 | -- |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 5.79, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | BBIO |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | -- |
| P/S Ratio (TTM) | 4.17 | 15.31 |
| P/B Ratio (MRQ) | 5.79 | -5.59 |
| Free Cash Flow Yield (TTM) | 1.57% | -1.98% |